Sign in
Taking peopleNo phase

Evaluation of Blood Protein O-GlcNAcylation Levels in Children

Key facts

Who runs it
Nantes University Hospital
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
240 people, planned
Started
30 Jan 2025
Expected to end
31 Jan 2036
Type of study
Observational, 2 groups
Record updated
12 November 2026

Who can take part

Age
Up to 17 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Age from 0 to 17 years at the time of sampling (including premature infants)
  • Children coming to hospital for a blood sample to be taken as part of a pre-operative check-up, an allergy check-up or a check-up as part of a pathology other than sepsis
  • Premature infants benefiting from a blood sample as part of their monitoring and management of prematurity
  • Collection of umbilical cord blood
  • Signed consent
  • Age from 0 to 17 years at the time of sampling (including preterm infants)
  • Children with suspected sepsis or diagnosed sepsis according to the 2016 definition
  • Premature infants having blood drawn for suspected or diagnosed sepsis
  • All responsible bacteria, viruses or fungi
  • Signed bio-collection consent

Who cannot take part

  • Children with an infection
  • Children with autoimmune disease
  • Children with metabolic disease
  • Children with haematological diseases
  • Children with a genetic disease
  • Children with autoimmune disease
  • Children with a metabolic disease
  • Children with haematological diseases
  • Children with a genetic disease
  • Children with fever
  • Children with an immune deficiency
  • Unsigned consent
  • Refusal by parents or child
  • Septic group
  • Children with an immune deficiency
  • Unsigned bio-collection consent
  • Refusal by parents or child

Other criteria

  • Healthy group

This trial is currently available in France.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Stimulation of O-GlcNAcylation has been shown to be beneficial in several acute pathologies and different animal models, such as haemorrhagic and septic shock, and ischaemia-reperfusion (cerebral and cardiac). It could therefore be interesting to use this approach in children in order to limit the impact of various pathologies inducing SIRS, such as extracorporeal circulation for major surgery, septic shock or various traumas. The investigators demonstrated in 2 different animal models (endotoxemia by injection of Lipopolysaccharides and caecal puncture ligation model) with 3 different pharmacological molecules (Glucosamine, ThiametG and NButGT) that stimulation of O-GlcNAcylation was beneficial in the early phase of septic shock with a marked effect on cardiac function and survival. The investigators thus demonstrated that stimulation of O-GlcNAcylation was beneficial in young rats in septic shock. However, none of this work has yet been reproduced in humans, either children or adults.

The 2 groups in the trial

  • Healthy group

    children attending hospital and receiving a blood sample as part of their care during general paediatric consultations, anaesthesia or day hospital consultations. Children requiring a blood test as part of a medical indication in the first week of life / blood samples taken at birth from cord blood. A blood sample will be taken at inclusion during a blood test carried out in the care unit, and possibly if other blood samples are planned as part of the care, additional samples will be taken in a maximum of 6 tubes in 48 hours, i.e. for a total volume of 600 µl to 3 ml. The child's clinical data will be collected in his medical file.

  • Septic shock

    Children attending a paediatric emergency department for a severe infection requiring vascular filling, or a child admitted to an intensive care unit for sepsis or presenting with sepsis during hospitalisation. A blood sample will be taken at inclusion during a blood test carried out in the care unit and then at H3, H6, H12, H24 and H48, i.e. 6 times in 48 hours for a total volume of 600 µl to 3 ml for patients in septic shock. The child's clinical data will be collected in his medical file.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of Blood Protein O-GlcNAcylation Levels in Children - CHANCE Study (Child Heart O-glcnAc Nantes)
Record updated
12 November 2026